Abstract
Background Bifidobacterium longum supplementation can be used to regulate bowel movement; however, individuals vary in the response to B. longum treatment. One putative factor is the gut microbiota; recent studies have reported that the gut microbiota mediates diet or drug effects. Here, we investigated intestinal features related to B. longum effectiveness in increasing bowel movement frequency.
Results A randomized, double-blind controlled crossover trial was conducted with twenty Japanese subjects selected from 50 participants. The subjects received a two-week dietary intervention consisting of B. longum in acid-resistant seamless capsules or similarly encapsulated starch powder. Bowel movement frequency was recorded daily, and time-series fecal collection was conducted for metabologenomic analyses. There were differences among subjects in B. longum intake-induced bowel movement frequency. The responders were predictable by machine learning based on the metabologenomic features of the fecal samples collected before B. longum intake. Between responders and non-responders, the abundances of nine bacterial genera and of three compounds were significantly different.
Conclusions Thus, the gut microbiome and metabolome composition have a strong impact on B. longum supplementation effectiveness in increasing bowel movement frequency, and gut metabologenomics enables B. longum supplementation effect prediction before intake. These findings have implications for the development of personalized probiotic treatments.
Trial registration UMIN-CTR, UMIN000018924. Registered 07 September 2015, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021894
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
UMIN000018924
Clinical Protocols
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021894
Funding Statement
None declared.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact: e-mail: yamada{at}metagen.co.jp, sfukuda{at}metagen.co.jp, tel: (+81) 235-64-0330
Data Availability
The raw sequencing dataset reported in this paper is available in the DDBJ Sequence Read Archive (DRA) repository (DRA006874; https://ddbj.nig.ac.jp/DRASearch/submission?acc=DRA006874). The metabolomic datasets by CE-TOFMS are included within the article and its additional files.
